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improving quality of life over extending life. ConClusions: Advanced NSCLC is 
known to impact many domains of patients’ lives. This study demonstrates that 
emotional impact and time taken undergoing treatment may be undervalued by 
commonly employed HRQoL metrics in clinical trials. Future clinical trials of new 
lung cancer treatments should include assessment of these concepts. Ultimately, 
HRQoL instruments should be identified/developed that satisfactorily capture all 
factors deemed important by patients in order to fully reflect impact of new treat-
ments on patients’ lives.
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PrefereNCe eliCitatioN oN BeNefits aNd risks of MediCiNes UsiNg a 
disCrete ChoiCe exPeriMeNt
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objeCtives: Differences in preferences for treatment outcomes are known to exist 
among patients and healthcare professionals, but rarely are data available that 
include the preferences of medical regulators. Methods: Discrete choice (DCE) 
methodology was applied via an online questionnaire among patients and experts 
(HCPs, European medical assessors) in three disease areas (atrial fibrillation (AF), 
breast cancer (BC) and type II diabetes (DB)) in the United Kingdom, France and 
the Netherlands. Selection of the attributes was made via focus group question-
naires among 150 patients in each disease area. Data for the required number of 
drug scenarios were compiled from existing medicines for the disease areas and 
participants were asked to choose the drug they preferred. An alternative-specific 
conditional logit model was used to evaluate the choices made for each pair of 
scenarios. Results: Data were collected from 1288 patients: 205 AF; 531 BC; 552 
DB. Data for HCPs and medical assessors present the expert view: 89 AF; 211 BC; 122 
DB. Atrial fibrillation patients chose the prevention of stroke as the most important 
attribute while for experts fatal bleeding was the most important attribute; all other 
attributes were given the same order of importance by both groups. For diabetes, 
both patients and experts indicated preventing cardiac disorders as most important 
attribute of a treatment. However, the order of the remaining attributes differed. For 
breast cancer, the order of importance of all the attributes was the same for patients 
and experts. The choices were not explained by demographic characteristics and 
disease severity had no impact on the choices made by patients. ConClusions: 
With the exception of breast cancer, the view that patients and experts have dif-
ferent preferences for treatment outcomes continues to be supported by this data. 
There may exist a chronic/acute illness axis that may differentiate the preferences 
between experts and patients.
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objeCtives: Recent initiatives within Europe to increase the involvement of 
patients in the regulation of medicines are positive actions. However, is there a 
shared view among European patients on the favorable and unfavorable outcomes 
of medicines? This study aims to assess differences in preferences for treatment 
outcomes across three countries in Europe. Methods: Data were collected via web-
questionnaires from patients diagnosed with atrial fibrillation (AF), breast cancer 
(BC) and type II diabetes (DB)) in the United Kingdom, France and the Netherlands. A 
panel of physicians, epidemiologists, and healthcare researchers reviewed favorable 
and unfavorable outcomes of current treatments and compiled a list of treatment 
outcomes. Patients were asked to rank by order of importance the treatment out-
comes specific to their area of disease. Results: A total of 454 patients provided 
data: age 20-75 years; predominantly female for DB and AF and all female for BC. 
AF patients across all countries ranked reduction in fatal ischemic stroke as the 
most favorable treatment outcome and fatal hemorrhage as the most unfavorable 
outcome. Dutch and British BC patients ranked overall survival as most favorable, 
while French BC patients selected health related quality of life. All BC patients 
selected cardiotoxicity as the most unfavorable outcome. Dutch and French DB 
patients ranked decreased fasting glucose as most favorable outcome, while British 
DB patients were divided between reduction in weight, reduction in hemoglobin and 
changes in blood pressure. Dutch and British DB patients ranked congestive heart 
failure as the most unfavorable outcome, while French patients selected hypogly-
cemia. ConClusions: Patient differences, as determined by demographics and 
disease characteristics, are commonplace in medical research; however exploration 
of country and regional differences in values and preferences among patients are 
less common and should be included in any research activity aimed at elucidating 
the representative patient voice for Europe.
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objeCtives: Novel treatments for advanced melanoma have been developed with dif-
fering levels of effectiveness, safety, cost, and route of administration. Understanding 
the preferences among these attributes between patients and physicians is necessary 
for quality treatment and shared decision making. In health care, Discrete Choice 
Experiment (DCE) is one of the recommended tools for eliciting treatment preferences 
by reflecting different perspectives and the trade-off between attributes. The objective 
of this study is to measure patient and physician preferences by conducting a DCE 
for advanced melanoma treatments with a special focus on immunotherapy and 
objeCtives: To determine the direct out-of-pocket expenses (co-payments) 
and overall satisfaction among patients enrolled in the Z Benefits for breast 
cancer. Methods: The database of paid claims was the sampling frame of the 
study. Participants were identified and trained data collectors conducted patient 
interviews using a pre-tested semi-structured survey tool. Participants signed an 
informed consent for an interview, audio and video documentation of feedbacks. 
Clinical data were extracted from medical records while out-of-pocket expenses 
were reviewed from statements of account and receipts of services received. 
Patient satisfaction during surgery, chemotherapy and overall patient satisfaction 
were validated with the satisfaction questionnaires submitted by the contracted 
hospitals. Results: A total of 80 claims for breast cancer using the Z benefit 
package were identified from July 2012 to August 2014 from five contracted hos-
pitals. Respondents underwent modified radical mastectomy with 50 patients 
receiving standard adjuvant chemotherapy. During hospital confinement, 41 
patients purchased medicines outside the hospital pharmacy. The overall aver-
age out-of-pocket expense was at Php 3600 (US$ 80). The average out-of-pocket 
expense was Php 4000 (US $ 89) for medicines, Php 1600 (US $ 36) for laboratory 
tests and Php 4200 (US $ 93) for professional fees which are within the allowed co-
payment limits. Patient satisfaction was generally good with satisfaction rates of 
98% and 92% for surgery and chemotherapy services, respectively. ConClusions: 
The overall patient satisfaction is favourable but there were still out-of-pocket 
expenses for medicines, laboratory tests and professional fees amounting to an 
average of Php 3,600 (US$80).
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objeCtives: To compare patient satisfaction with intravenous rituximab (RIV) 
versus subcutaneous rituximab (RSC) using the reliable and validated instrument, 
Rituximab Administration Satisfaction Questionnaire (RASQ). Methods: PrefMab 
(NCT01724021) is a randomized, open-label, crossover Phase IIIb study in patients 
with untreated CD20+ diffuse large B-cell lymphoma or follicular lymphoma (grade 
1–3a). Patients received chemotherapy (6–8 cycles CHOP [cyclophosphamide, doxo-
rubicin, vincristine, prednisone], CVP [cyclophosphamide, vincristine, prednisone], 
or bendamustine) plus 8 cycles of rituximab; Arm A: 1 cycle RIV (375 mg/m2) and 
3 cycles RSC (1400 mg) then 4 cycles RIV; Arm B: 4 cycles RIV (375 mg/m2) then 
4 cycles RSC (1400 mg). The general Cancer Therapy Satisfaction Questionnaire 
(CTSQ), and RASQ, were conducted at cycles 4 and 8; domains for both question-
naires were scored 0 (least)–100 (best). Adverse events were monitored through-
out. Results: At the primary data cut, January 19, 2015, the intent-to-treat 
population was: Arm A, n= 372; Arm B, n= 371. Median age was 60 years (range 
18–80). Baseline characteristics were balanced between arms. Overall median 
CTSQ scores with RSC and RIV were similar for all domains: expectations, side 
effects, and satisfaction with therapy. Overall median RASQ scores were higher 
for RSC versus RIV for psychological impact (88 vs 80), impact on daily living (83 
vs 58), convenience (83 vs 58), and satisfaction with therapy (88 vs 75), with no 
difference for physical impact. Overall, most patients considered time required 
to administer R was ‘just right’ (88% SC vs 56% IV), and they had ’more than 
enough time’ to discuss concerns with their doctors/nurses (79% SC vs 79% IV). 
Treatment sequence did not impact CTSQ or RASQ scores. No new safety signals 
were detected. ConClusions: Patient satisfaction with R-chemotherapy was 
comparable for RSC and RIV. However, rituximab-specific satisfaction measured 
by RASQ was generally greater with RSC than RIV.
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objeCtives: The aim of this study was to better understand the impact of 
advanced NSCLC and its treatment on the quality of life and experience of 
patients, in order to inform the design and inclusion of outcome assessments in 
clinical trials. Methods: Face-to-face, qualitative, semi-structured interviews were 
conducted with 20 UK participants with advanced NSCLC. Interviews explored par-
ticipants’ experiences of aNSCLC and the treatment they received. Open-ended 
questioning (facilitating spontaneous reporting), was followed by focused questions 
to further investigate important themes. Creative methods including an impact rat-
ing ladder and timeline task were used to elicit content. Verbatim transcripts were 
analyzed using a data-driven, thematic analysis approach. Results: Participants 
experienced considerable burden from symptoms and treatment-related side effects 
(e.g. breathlessness, nausea), which left them unable to participate in activities 
of daily living such as housework, shopping or going outside. However, partici-
pants reported that the emotional impact on them and their families (e.g. worry, 
sadness and frustration) had the biggest negative impact on their lives. Almost 
all participants were highly satisfied with their treatment and care, but time lost 
to receiving and recovering from treatment was commonly reported. Efficiency, 
communication and practical and emotional support were aspects of care valued 
most by participants. The majority of participants asked said they would prioritise 
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objeCtives: We explored the temporal relationship between PRO changes, which 
are used to measure therapeutic impact, and subsequent clinical outcomes in 
mCRPC. Methods: COU-AA-301 was a multinational, double-blind, randomized 
phase 3 trial of abiraterone acetate plus prednisone compared with prednisone alone 
in mCRPC patients progressing after chemotherapy, with an Eastern Cooperative 
Oncology Group performance status of ≤ 2. Using data from COU-AA-301 (N = 1195) 
over the first 181 days of treatment, we explored relationships between changes 
in clinical time-to-event outcomes and PROs measuring fatigue, pain, physical 
well-being (PWB), functional well-being (FWB), and prostate cancer–specific signs 
and symptoms. Cox regression models were developed to assess the relationship 
between each PRO (separately and for all simultaneously), and overall survival 
(OS) and radiographic progression-free survival as dependent variables, adjusting 
for important baseline clinical and PRO characteristics. Results: In each indi-
vidual model, patients with PRO improvements had a reduced risk of death and 
radiographic progression compared with patients with worsening or stable PROs 
during follow-up. Hazard ratios (95% confidence intervals) for OS in patients with 
improved fatigue intensity, pain intensity, PWB, FWB, and prostate cancer-specific 
symptoms were 0.17 (0.11-0.24), 0.27 (0.18-0.41), 0.12 (0.07-0.22), 0.21 (0.12-0.35), and 
0.19 (0.12-0.28), respectively (all p < 0.0001). A significant (p < 0.0001) reduction in 
the risk of radiographic progression was seen in patients with improvements in 
fatigue intensity [0.59 (0.48-0.72)], pain intensity [0.52 (0.41-0.65)], PWB [0.47 (0.37-
0.60)], FWB [0.55 (0.44-0.69)], and prostate cancer–specific symptoms [0.56 (0.46-
0.67)]. When all end points were included in a single multivariate model, all except 
pain intensity were significantly associated with OS, whereas pain intensity, PWB, 
and FWB improvements remained significantly associated with reduced risk of 
radiographic progression. ConClusions: These results demonstrate a significant 
temporal relationship between PROs and clinical outcomes, and may complement 
clinical practice methods for monitoring patients for progression.
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objeCtives: Cognitive dysfunction is a common concern for children with brain 
tumors and those who received neuro-toxic treatment. Child- and parent-reported 
cognitive function (PCF) could be used to monitor children’s cognitive performance 
overtime given their ease of administration, low cost and relevance to patients’ daily 
lives. Understanding factors contributing to discordance between child- and parent-
reported PCF could help investigators better interpret PCF. This study aims to evaluate 
whether rating scale types (intensity versus frequency) and disease status (cancer 
versus general population) influence the agreement between child- and parent-
reported PCF. Methods: Data from 1,409 children (mean age= 12 yrs) drawn from 
the US general population and their parents and 515 children with cancer (53% brain 
tumor; mean age= 14 yrs) were analyzed. For cancer sample, 34% received radiation 
therapy, 72% chemotherapy, 71% surgery and mean years post-treatment = 3.3. All 
completed two versions of a validated pediatric perceived cognitive function short-
form (pedsPCF-SF). Both had the same 13 item stems but with different 5-point rating 
scales: 1) “frequency” (“none of the time” -- “all of the time”) and 2) “intensity” (“not 
at all” -- “very much”). Weighted Kappa was used to evaluate agreement at individual 
item level between parent- and child-reported pedsPCF-SF. Intra-class correlation 
(ICC) was used to evaluate agreement at the scale level. Results: For cancer sample, 
weighted kappas between children and parents were 0.27-0.39 for both intensity and 
frequency. For general population, weighted kappas were 0.53-0.67 and 0.64-0.70 for 
intensity and frequency, respectively. At the scale level, higher agreement was found 
on general population sample (ICC= 0.77 and 0.81 for intensity and frequency, respec-
tively) than cancer sample (ICC= 0.46 and 0.38, respectively). ConClusions: Higher 
agreement was found on general population children/parents dyads compared to 
those with cancer/brain tumors at both item and scale levels. Results from this study 
can be applied to improving assessment in future pediatric studies.
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objeCtives: Patient reported outcome (PRO) tools at our institution have focused 
traditionally on in-clinic evaluation. In anticipation of real time home electronic 
reporting, we assessed whether patients were willing to complete symptom/toxicity 
PRO tools prior to their clinic visits. Such tools may be more accurate and reliable but 
depend on patient motivation. Methods: One hundred and seventy-two cancer 
outpatients were recruited at the Princess Margaret Cancer Centre. Patients were 
surveyed on their preferences for completing a currently established institutional 
electronic symptom/toxicity PRO tool when administered outside the clinic on an 
electronic platform, such as on a tablet or smartphone. Results: The median par-
ticipant age was 56.5 years and 58% were female. 74% were Caucasian and 67% had 
some post-secondary education; 58% had local disease. Of the participants, 48% 
(83/172) indicated that they would not wish to complete the PRO tool in advance of 
attending their clinic appointments and only 15% (25/172) agreed or strongly agreed. 
Fair to moderate agreement (weighted kappa= 0.41) existed between willingness/
unwillingness to complete the PRO tool in advance and willingness/unwillingness 
to fill it out electronically. Lack of willingness was not associated with any clinico-
demographic factors. Patients generally felt that the tool was not difficult to use 
(91%) and did not take too long (81%) to complete. ConClusions: Patients were 
not willing to fill out a PRO tool electronically in advance of clinic visits, even though 
BRAF/MEK inhibition. Methods: To develop a DCE to assess preferences between 
immunotherapy options (PD-1 and/or CTLA-4 inhibition) and BRAF/MEK inhibition, a 
literature review was conducted and stakeholder interviews with melanoma patients 
and oncologists were performed to determine treatment attributes and levels. The 
final survey will consist of three parts (demographics, treatment preferences, and 
the DCE section) and will be administered to patients and their treating physicians 
at the Huntsman Cancer Institute at the University of Utah. Results: The general 
information in the survey, the defined attributes and levels for melanoma treatment, 
and DCE questionnaires will be reported. The target sample for survey administra-
tion is 200 patients and up to 60 physicians. A total of 485 patients with melanoma 
within the University of Utah Health Care system are available to survey and include 
378 patients with stage I, 81 with stage II, 6 with stage III, and 20 with stage IV mela-
noma. ConClusions: DCE is a potential avenue to assess patient and physician 
preferences in innovative melanoma treatments. Understanding how patients and 
physicians can be jointly involved in understanding trade-offs in treatment decisions 
will provide valuable insight into the acceptance and optimize utilization of these 
agents for the treatment of melanoma.
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objeCtives: The main objective of our study was to assess a sample of the popula-
tion’s knowledge on breast cancer and screening and also to assess women’s willing-
ness to participate in the screening. Methods: The quantitative, cross-sectional 
questionnaire survey was performed among women in two Hungarian counties. 
130 questionnaires were distributed, of which 118 proved to be evaluable. The study 
was performed in 2014 with χ 2-test as a statistical method besides 95% probability 
(p< 0.05). We used SPSS version 20.0 program. Results: The respondent women’s 
average age was 50.87±5.7SD years. 83.9% of the respondent women went to breast 
cancer screening due to an invitation letter. The respondents named the gynecolo-
gist as the most reliable source of information. Significantly more (χ 2= 9.07, p= 0.015) 
women over 50 years of age (85.7%) stayed away from screening without their doctor’s 
proposal than those of under 50 years of age (14.3%). Significantly more women with 
primary education (χ 2= 9.41 p= 0.007) stayed away from screening due to the cost than 
those with higher education. 85% of the respondent women heard about breast self-
exam. The main source of information about it is the media among the respondent 
women. 25 of them did self-exam each month. Despite of high participation rates the 
respondent women’s knowledge was superficial. On the basis of the questions con-
cerning knowledge on breast cancer risk factors and symptom only 36% of the women 
had adequate knowledge. Women with health education (χ 2= 20.00, p= 0.001) were 
significantly better informed on the issues than their counterparts. ConClusions: 
Women reported an extremely high participation rate in breast screening, however, 
the overall knowledge about breast cancer of the respondents is superficial. The high 
participation rates were due to the invitation letter and the gynecologist. In the future, 
their triggering role is needed to enhance women’s awareness.
PCN225
a disCrete ChoiCe exPeriMeNt for eNgagiNg PatieNts iN 
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objeCtives: Over recent years, decision makers worldwide have emphasized the 
need to engage patients in healthcare policies, such as considering patient values 
in reimbursement decision making. However, integrating the preferences of numer-
ous patients towards complex healthcare technologies is challenging. We aim to 
generate patient preferences towards adjuvant chemotherapy, by deconstructing 
such preferences into different attributes. Methods: We apply a discrete choice 
experiment to measure the relative preferences on the treatment route, length of 
treatment, accompanying cardiac toxicity, absolute relapse risk reduction and out-
of-pocket payments. We further estimate the marginal ‘willingness-to-pay’ (WTP) 
for the favored characteristics. Staff at medical center Breast Surgery Clinics carried 
out interviews with 106 patients with Stage I or Stage II breast cancer. Each par-
ticipant was asked to complete 12 formal choice tasks, with the participants being 
invited to choose one of two treatments in each choice task, or to opt out. Results: 
Our findings reveal that daily oral intake, monthly injections and a reduction in 
relapse risk were all favored by the participants, whereas quarterly injections, 
accompanying cardiac toxicity and additional out-of-pocket payments were not. 
The marginal WTP for a 2 per cent (5 per cent) reduction in relapse risk, was 1.10 
times (3.30 times) per capita GDP in Taiwan, whilst that for avoiding cardiac toxicity 
was about 1.43 times per capita GDP. The participants also had a WTP of 0.28 times 
(1.10 times) per capita GDP for a change in their treatment regimen from monthly 
(quarterly) injections to daily oral intake. ConClusions: The controversy between 
decision makers and certain groups of patients, with regard to the preference among 
the latter for longer dosing intervals, reveals an urgent requirement for increased 
education and dialogue for both of these groups of stakeholders, along with the 
involvement of patients in decision making.
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